Lindsey A Herrel
Clinical Associate Professor of Urology
Core Educational Lead and Medical Director
Operating Rooms
[email protected]

Available to mentor
Lindsey A Herrel
Clinical Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Journal Article
      Understanding the impact of historical redlining on prostate cancer care quality and treatment patterns and the association with modern metrics of disparity.
      Zebib L, Herrel LA, Dunn R, Sekar R. Journal of Clinical Oncology, 2024 Oct; 20 (10_suppl): 118 - 118. DOI:10.1200/op.2024.20.10_suppl.118
    • Journal Article
      Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer.
      Sekar RR, Irani S, Maganty A, Montgomery JS, Herrel LA. Urology, 2024 Sep; 191: 79 - 84. DOI:10.1016/j.urology.2024.05.006
      PMID: 38763474
    • Journal Article
      Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors.
      Sekar RR, Maganty A, Stensland KD, Herrel LA. JCO Oncol Pract, 2024 Aug 29; OP2400206 DOI:10.1200/OP.24.00206
      PMID: 39208361
    • Journal Article
      Individual- and Community-Level Risk Factors of Cancer-Related Financial Hardship Among Cancer Survivors.
      Dhir A, Stensland KD, Herrel LA, Sekar RR. JAMA Netw Open, 2024 Aug 1; 7 (8): e2429286 DOI:10.1001/jamanetworkopen.2024.29286
      PMID: 39163047
    • Journal Article
      Estimating the Size and Scope of the Urologic Oncology Clinical Trials Enterprise.
      Stensland KD, Krischak MK, Bank M, Sekar RR, Lewicki P, Piatt GA, Ghani K, Herrel LA, Barnes GD, Odell DD, Skolarus TA. Urol Pract, 2024 Jul; 11 (4): 627 - 629. DOI:10.1097/UPJ.0000000000000598
      PMID: 38899679
    • Journal Article
      Quality of care for dual eligible beneficiaries in the oncology care model.
      Liang X, Zhu Z, Faraj K, Shahinian VB, Hollenbeck BK, Herrel LA. Cancer Med, 2024 Jul; 13 (14): e70009 DOI:10.1002/cam4.70009
      PMID: 39030893
    • Journal Article
      The 340B Program and oral specialty drugs for advanced prostate cancer.
      Faraj KS, Kaufman SR, Oerline M, Herrel LA, Maganty A, Caram MEV, Shahinian VB, Hollenbeck BK. Cancer, 2024 Jun 15; 130 (12): 2160 - 2168. DOI:10.1002/cncr.35262
      PMID: 38395607
    • Journal Article
      Abstract A009: Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response
      Merrill NM, Kaffenberger SD, Bao L, Vandecan N, Goo LE, Apfel A, Cheng X, Qin Z, Liu C-J, Bankhead A, Wang Y, Kathawate V, Tudrick L, Serhan H, Farah Z, Ellimoottil C, Hafez KS, Herrel LA, Montgomery JS, Morgan TM, Salami SS, Weizer AZ, Ulintz PJ, Day ML, Soellner MB, Palmbos PL, Merajver SD, Udager AM. Clinical Cancer Research, 2024 May 17; 30 (10_Supplement): A009 - A009. DOI:10.1158/1557-3265.bladder24-a009